Ustekinumab
Stock Recap #PipelineProspector

Pipeline Prospector Jan 2024: Vertex’s non-opioid painkiller succeeds in trials; Sanofi buys Inhibrx for US$ 2.2 bn

The New Year got off to a stable start, with some good news trickling in from clinical trials and B